TVTX

SEC source: 0001209191-22-006369 · doc4.xml · derivative · entry 4

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,840

Underlying: Common Stock · 9,840 shares

Expires not disclosed

F4 · derivative.exercise_price: Each PRSU represents a contingent right to receive one share of the Common Stock of the Issuer.

F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006369 · doc4.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,360

Underlying: Common Stock · 39,360 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-006369 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,788

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006369 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,138

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-22-006367 · doc4.xml · derivative · entry 5

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F6 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

F6 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006367 · doc4.xml · derivative · entry 4

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,840

Underlying: Common Stock · 9,840 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006367 · doc4.xml · derivative · entry 3

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,360

Underlying: Common Stock · 39,360 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-006367 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,235

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006367 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,360

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-22-006363 · doc4.xml · derivative · entry 5

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F6 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

F6 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006363 · doc4.xml · derivative · entry 4

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,840

Underlying: Common Stock · 9,840 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006363 · doc4.xml · derivative · entry 3

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,360

Underlying: Common Stock · 39,360 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-006363 · doc4.xml · nonDerivative · entry 2

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,297

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006363 · doc4.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,422

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-22-006362 · doc4.xml · derivative · entry 5

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F6 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

F6 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory milestones, provided, however, if the vesting events occur before the date that is 24 months after the date of grant, then the award will instead vest on the date that is 24 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2026 if the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006362 · doc4.xml · derivative · entry 4

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,840

Underlying: Common Stock · 9,840 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006362 · doc4.xml · derivative · entry 3

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,360

Underlying: Common Stock · 39,360 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-006362 · doc4.xml · nonDerivative · entry 2

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,855

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006362 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,093

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-22-006357 · doc4.xml · derivative · entry 4

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,848

Underlying: Common Stock · 37,848 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

F5 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

F5 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31, 2027 to the extent the specified performance based milestones are not achieved by such date.

SEC source: 0001209191-22-006357 · doc4.xml · derivative · entry 3

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,552

Underlying: Common Stock · 169,552 shares

Expires 2032-01-30

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-006357 · doc4.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,745

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-006357 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,558

F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan that are scheduled to vest over four years.

SEC source: 0001209191-22-005084 · doc4.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · VP, Corp Controller and CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,662

F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

F2 · balance_after: Includes 842 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.

SEC source: 0001209191-22-005083 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,520

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-005082 · doc4.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,582

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-005081 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,298

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-005080 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,253

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-005078 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,710

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-003053 · doc4.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,548

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-003046 · doc4.xml · nonDerivative · entry 2

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,316

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-003050 · doc4.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,395

F3 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001209191-22-003053 · doc4.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,548

F1 · kind: On January 4, 2017, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 5,000 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.

SEC source: 0001209191-22-003046 · doc4.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,816

F1 · kind: On July 1, 2015, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 7,500 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.

SEC source: 0001209191-22-003050 · doc4.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,895

F1 · kind: On February 13, 2017, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 15,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified performance milestones. On January 10, 2022, PRSUs covering 5,000 shares of the Issuer's common stock vested upon the Issuer's confirmation that the Issuer's fiscal 2021 net reported revenue exceeded $200 million.

F2 · balance_after: The reporting person's Form 4 filed August 17, 2021 overstated the number of shares of the Issuer's common stock acquired by the reporting person on May 31, 2021 pursuant to an employee stock purchase program in the amount of 399 shares. The number of shares set forth in column 5 above has been adjusted to correct such overstatement and to include 563 shares of the Issuer's common stock acquired by the reporting person on November 30, 2021 pursuant to an employee stock purchase program.

SEC source: 0001209191-22-002156 · doc4.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,583

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.38 to $30.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-22-002156 · doc4.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,722

F2 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.38 to $30.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-22-002156 · doc4.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,083

F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-22-001117 · doc4.xml · derivative · entry 2

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-12-31

F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-22-001117 · doc4.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

SEC source: 0001209191-21-065439 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,494

F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.05 to $29.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3 · balance_after: Includes 19,500 shares previously reported as indirectly held in the name of the Aselage Family Trust.

SEC source: 0001209191-21-063591 · doc4.xml · derivative · entry 4

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 10,000 shares

Expires 2026-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001209191-21-063591 · doc4.xml · nonDerivative · entry 2

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,794

F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-21-063591 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 6

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 19,500

F2 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F1 · ownership.nature: The shares are held in the name of the Aselage Family Trust.

SEC source: 0001209191-21-062670 · doc4.xml · nonDerivative · entry 5

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 23,000

F2 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.065 to $29.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F1 · ownership.nature: The shares are held in the name of the Aselage Family Trust.

SEC source: 0001209191-21-060035 · doc4.xml · derivative · entry 4

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 60,000 shares

Expires 2026-05-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001209191-21-060035 · doc4.xml · nonDerivative · entry 3

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,794

F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-21-060035 · doc4.xml · nonDerivative · entry 2

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,794

F1 · kind: The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

SEC source: 0001209191-21-060035 · doc4.xml · nonDerivative · entry 1

ASELAGE STEVE · CIK 0001221599 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.